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Abstract 
Background: DNA integrity analysis could represent an alternative approach to the 
early detection of colorectal cancer (CRC). Previously, fluorescence long DNA (FL-
DNA) in stools was extracted using a manual approach and analysed by capillary 
electrophoresis assay (CE FL-DNA). We aimed to improve diagnostic accuracy using  a 
simpler and more standardised method (Real Time PCR FL-DNA [RT FL-DNA]) for 
the detection of early malignant lesions in a population undergoing CRC screening.  
Methods: From 241 stool samples, DNA was extracted using manual and semi-
automatic extraction systems and analysed using FL-DNA tests by CE and RT assays. 
The RT FL-DNA approach showed slightly higher sensitivity and specificity compared 
to the CE FL-DNA method. Furthermore, we compared the RT FL-DNA approach with 
the iFOBT report.  
Results: Non-parametric ranking statistics were used to analyse the relationship 
between the median values of RT FL-DNA and the clinico-histopathological 
characteristics. The median values of both variables were significantly higher in cancer 
patients than in patients with non-cancerous lesions. According to the Fagan nomogram 
results, iFOBT and FL-DNA methods provided more accurate diagnostic information 
and were able to identify subgroups at varying risks of cancer.  
Conclusions: The combination of the semi-automatic extraction system and RT FL-
DNA analysis improved the quality of DNA extracted from stool samples.  
Impact: RT FL-DNA shows great potential for colorectal cancer diagnosis as it is a 
reliable and relatively easy analysis to perform on routinely processed stool samples in 
combination with iFOBT.  
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Introduction 
 Colorectal cancer (CRC) is the third most common form of cancer and the second 
leading cause of deaths among cancers worldwide (1). Sporadic colon cancer, which 
represents 70% of newly diagnosed cases, develops via the progressive accumulation of 
multiple mutations that affect tumour suppressor genes, as well as oncogenes or 
mismatch repair genes (MMR) (2). 
 Several studies have shown that colorectal cancer screening programmes are able to 
reduce cancer mortality (3-5). Strategies used in screening programmes, which differ 
according to geographical areas, can be classified into three broad categories: stool tests 
(faecal occult blood test [FOBT]), endoscopic examinations (flexible sigmoidoscopy 
and colonoscopy) and imaging tests (double contrast barium enema or computed 
tomographic colonography) (3, 6).  
 Nevertheless, none of these methods is truly optimal due to different technical limits. 
FOBT is a cheap, non-invasive test but it has several limitations, such as: low 
sensitivity, especially in detecting pre-cancerous lesions, and low ability to distinguish 
benign and malignant pre-cancerous lesions compared to endoscopic examinations (7). 
Moreover, the low specificity of occult blood test leads to a high number of unnecessary 
colonoscopies (8). All patients with a positive iFOBT are invited to undergo a 
colonoscopy examination, but it is estimated that only 50% of individuals at average 
risk of the development of CRC comply with current screening guidelines and agree to 
the medical examination (9, 10). Conversely, endoscopic and imaging examinations are 
more accurate but are more expensive and invasive, thus reducing compliance in 
screening programmes (6). The main difficulties involved in undergoing colonoscopies 
include psychological barriers, such as fear of the procedure and embarrassment, as well 
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as procedural problems, such as the requirement for a cathartic preparation, sedation, 
and the inherent risks of complications and discomfort associated with colonoscopies 
(11). All these points represent potential reasons for individuals to avoid undergoing this 
crucial preventive health test (12), which has been shown to be able to reduce mortality 
related to the CRC disease (13). 
 Many new molecular non-invasive screening tests have been developed and 
investigated for the detection of CRC. Faecal DNA tests have been designed to detect 
molecular abnormalities present in pre-cancerous or cancerous lesions: chromosomal 
instability due to abnormalities in mutational hotspots like APC, KRAS, and TP53; 
microsatellite instability (MSI); and alteration of DNA methylation status (14-15).  
The factors that limit the widespread diffusion of these methodologies are related to 
time-consuming approaches and poor cost-effectiveness compared to other screening 
tests. In fact, despite good sensitivity and specificity compared to iFOBT, the actual 
costs for analyses with molecular tests are too high to suggest their use in screening 
programmes (6).  
 In order to identify a new approach, which is relatively cheap and not time-
consuming, able to increase accuracy in detecting colorectal lesions, in recent years, we 
studied stool DNA integrity as a molecular marker that could help to improve the identi-
fication of colorectal cancers (CRC) and to determine a patient's risk of harbouring a 
pre-neoplastic or neoplastic lesion (16-19).  
 For this purpose, we carried out a quantitative evaluation based upon fluorescence 
amplification of different genomic DNA targets and quantification by capillary 
electrophoresis and reference standard curve, fluorescence long DNA (FL-DNA)      
(16-19). After completing pilot and confirmation case-control studies (17, 19) and 
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further to an initial evaluation of the combination of this test with iFOBT (19), the aim 
of this study is to devise a standardised method, based upon Real-Time PCR analysis 
combined with a semi-automatic extraction of stool DNA, which is simpler and easier 
to perform than previously described approaches, so as to improve the accuracy of FL-
DNA in detecting pre-malignant and malignant lesions (16-19).  
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Materials and Methods 
Patient sample 
 All study subjects were recruited from the Gastroenterology and Digestive 
Endoscopy Units of the Morgagni-Pierantoni” Hospital (Forlì, Italy) and the “Castel 
San Pietro Terme” Hospital (Bologna, Italy) by two methods: a regional screening 
programme or direct access to the Medical Unit. Informed consent was obtained from 
all individuals agreeing to take part in the study. A total of 241 individuals were enrolled 
in the study with a medical report of colonoscopy within 45 days of the result of the 
iFOBT test. Of these, 23 were diagnosed with adenocarcinomas, 34 with high-risk 
adenomas and 35 with low-risk adenomas. One hundred and forty- nine individuals did 
not show any malignant or premalignant lesion. All individuals were submitted to 
endoscopic examination in order to confirm the diagnosis. The lesion type was 
histologically confirmed and, in cancer patients, the pathologic stage was defined in 
accordance with Dukes' classification. Pre-neoplastic lesions were classified as low or 
high-risk according to the National Comprehensive Cancer Network guidelines (20).  
 Specifically, all patients were considered at high-risk when they had high-risk 
dysplasia, >3 adenomatous villous or tubulovillous polyps, at least one of which with a 
diameter of ≥1 cm, or an in situ carcinoma, whereas those who presented <3 tubular 
polyps with a diameter <1 cm were considered at low-risk (19). The study protocol was 
reviewed and approved by the local ethics committee.   
Sampling 
 Stool samples were collected using the OC-Sensor device (Alfa Wassermann, 
Bologna, Italy). Subjects were provided with instructions for collecting the faecal matter 
at home and were informed that the samples had to be brought to the analysis laboratory 
on October 4, 2014. © 2014 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 15, 2014; DOI: 10.1158/1055-9965.EPI-14-0379 
                                                                                                       FL-DNA method for CRC early detection 
8 
 
within 24 hours. In accordance with regional guidelines for colorectal cancer screening, 
test positivity was defined as a haemoglobin value ≥100 ng/ml. Haemoglobin values 
were determined using an immunochemical technique. The same specimen was used for 
iFOBT and molecular analyses. Immediately after occult blood tests, samples were 
processed for DNA extraction or stored at -20°C for a maximum of two months on the 
basis of results from preliminary experiments on DNA stability (19).  
   
DNA extraction: 
Manual approach 
 A QIAamp DNA Stool Kit (Qiagen, Hilden, Germany) was used for stool DNA 
purification as previously described (19). 
Semi-automatic extraction 
 Five hundred microliters of helix tissue buffer (Diatech Pharmacogenetics, Jesi, 
Italy) were added to the frozen pellet and after solution homogenisation, the samples 
were centrifuged at 13000 rpm for 1 minute.  A volume of 450 µl of supernatant was 
transferred to a new collection tube containing 8 µl of Helix Proteinase K (Diatech 
Pharmacogenetics) and mixed thoroughly for 15-20 seconds.  The solution was then 
were then incubated at 65°C for30 minutes, agitating constantly (V=500 rpm). The 
samples were then left to cool at room temperature and mixed for 15-20 seconds. After 
brief centrifugation, 400 µl from each sample was transferred into a HES Lysis Plate. 
From this step onwards the “HELIX DNA strip vc400-ve60 v200807_stool” protocol 
was applied using the Helix Extraction System (Diatech Pharmacogenetics).  
FL-DNA analysis: 
Capillary electrophoresis (CE FL-DNA) 
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FL-DNA was determined by PCR with fluorescent-labelled primers and capillary 
electrophoresis as previously described (19). All samples were run in duplicate and only 
inter-sample variations of <15% were accepted.  In all other cases (15% of the series), 
the determination was performed again and only <10% variations were accepted for the 
entire series. No samples showed variations >10% at this third evaluation. 
Real-Time PCR (RT FL-DNA)  
FL-DNA was analysed by Real-Time PCR.  The following reagents were added at the 
stool sample 5 µl used: Eurogentec MESA GREEN 1X 12.5 µl and Oligo-MixA 2 µl or 
Oligo-MixB 2 µl. Water5.5 µl was added to reach the final volume of 25 µl. Oligo-
MixA is composed of fragments 2 and 3 of APC exon 15  and exon 8 of p53. Oligo-
MixB is composed of fragment 4 of APC exon 8 and exons 5 and 7 of p53. Two mixture 
reactions were amplified simultaneously in the same programme composed of 41 
cycles: one cycle at 95°C for 5 minutes and 40 cycles at 94°C for  30 seconds, 59°C for  
30 seconds and 72°C for 30 seconds. Fluorescence was acquired during PCR at 77°C 
for Oligo-Mix A and at 80°C for Oligo-Mix B to select only signals coming from 
specific amplification products. The reaction specificity was further checked by a post-
PCR Melting Curve. Reaction was carried out using a Rotor Gene 6000 (Qiagen) 
equipped with Rotor Gene 6000 Series Software 1.7 (Build 87). The final FL-DNA 
value was obtained by analysing the fluorescence intensity of each sample-specific PCR 
product against a reference standard curve (5, 0.5 and 0.1 ng/reaction) of genomic 
DNA, expressed as ng/reaction. All samples were run in duplicate and only inter-sample 
variations of <15% were accepted. 
Statistical analysis  
 The objective of this study was to compare manual and semi-automatic systems to 
on October 4, 2014. © 2014 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 15, 2014; DOI: 10.1158/1055-9965.EPI-14-0379 
                                                                                                       FL-DNA method for CRC early detection 
10 
 
identify the best and least labour-intensive extraction system.  FL-DNA concentrations 
were considered as a continuous variable and the median values between these 
methodologies were compared using the non-parametric ranking median test. The 
analysis of the FL-DNA concentration in the two methodologies was carried out by 
receiver operating characteristic (ROC) curve analysis. In the ROC curves, true positive 
rates (sensitivity) were plotted against false positive rates (1-specificity) for all 
classification points. Sensitivity, specificity and their relative   95% Confidence 
Intervals (95% CI) were calculated using different cut-off values and the FL-DNA 
accuracy was measured using the Area Under ROC curve (AUC). Median values of RT 
FL-DNA and iFOBT between different types of lesions were compared using the 
Kruskal-Wallis test. Non-parametric ranking statistics (median test) were used to 
analyse the relationship between the median values of RT FL-DNA and the clinico-
histopathological characteristics. In order to estimate post-test probability, i.e., the 
probability of disease in a subject after the diagnostic test results are known, we first 
estimated the pre-test probability and determined the likelihood ratio. The pre-test 
probability is the chance of having the disease prior to testing and this is usually related 
to the disease prevalence. The likelihood ratio is the ratio of the probability of the 
specific test result in people who do have the disease to the probability in people who 
do not. The results were divided into three classes according to different cut-off values 
(0-9, 10-30, and ≥30 ng/reaction) to determine the FL-DNA likelihood ratio, which was 
calculated by dividing the percentage of patients with colorectal cancer by the 
percentage without the disease in each class. Finally, post-test probability was 
calculated by multiplying the likelihood ratio of the diagnostic test by the pre-test 
probability. All P values were two-sided and values ≤ 0.05 were considered statistically 
on October 4, 2014. © 2014 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 15, 2014; DOI: 10.1158/1055-9965.EPI-14-0379 
                                                                                                       FL-DNA method for CRC early detection 
11 
 
significant. Statistical analyses were carried out using SAS Statistical Software (version 
9.3, SAS Institute, Cary, NC, USA). 
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Results 
 In the previous works (16-19), analyses were performed using a manual approach to 
extract DNA from stool and the CE FL-DNA analysis method was used to evaluate 
DNA integrity. In an effort to improve this methodological approach, we divided our 
study into two phases. In the set-up phase, we detected the best stool DNA extraction 
method between the manual and semi-automatic systems, in combination with the best 
analytic tools between CE and RT FL-DNA. Secondly, we compared the efficiency of 
the semi-automatic extraction system and the RT FL-DNA analysis method, the tool 
found to be best, with the current screening test used, iFOBT. We performed both steps 
on the overall series of 241 individuals. 
DNA extraction optimisation 
 In order to set up the best DNA extraction method, the new semi-automatic approach 
and the standard manual protocol were tested in parallel. Starting with an amount of    
10 mg of faeces per sample, the DNA obtained using these two extraction approaches 
was amplified by two different multi-locus PCR and analysed by gel electrophoresis 
showing that the semi-automatic system allows for higher yields of amplification 
products (data not shown). In order to verify whether any Taq inhibitors were present in 
the DNA solution, the DNA samples were analysed by inhibition plasmid control. To 
this purpose, 25 ag of a plasmid containing a 150-bp non-human insert flanked by 
hybridisation regions for APC fragment 3 primers were added to each sample and 
amplified according to the CE FL-DNA protocol. In the absence of Taq inhibition, the 
150-bp fragment was detectable by capillary electrophoresis. Approximately 23% of 
DNA samples extracted by manual approaches presented DNA inhibition. For these 
samples it was necessary to make a further precipitation with ammonium-
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acetate/isopropanol to remove all inhibitors. Using the semi-automatic extraction 
method, the percentage of inhibition was reduced to only 3%. 
FL-DNA analysis evaluation: comparison between the two methods 
 DNA integrity was evaluated for all 241 stool samples using two methods: FL-DNA 
analysis was performed by CE and by RT FL-DNA. ROC curve analysis for CE FL-
DNA showed an area under the curve (AUC) of 0.81 (95% CI: 0.71-0.92); similarly, 
ROC curve analysis for RT-DNA showed an AUC of 0.82 (95% CI: 0.70-0.94)    
(Figure 1). 
The best cut-offs seem to range from 10 to 30 ng for both approaches.  The capillary 
electrophoresis approach seems to confirm the previous best cut-off of 25 ng in 
detecting tumours (18), with 57% (37-74; 95% CI) sensitivity and 84% (79-89; 95% CI) 
specificity and 82% (76-86; 95% CI) accuracy (Table 1). Conversely, using the RT FL-
DNA method, the best cut-off seems to be slightly lower. In particular, the cut-off of 15 
ng showed 70% (49-84; 95% CI) sensitivity in detecting tumours, 87% (82-91; 95% CI) 
specificity and 85% (80-89; 95% CI) accuracy. With a higher cut-off of 20 ng, the 
sensitivity decreased to 61% (41-78; 95% CI) but, conversely, an increase of specificity 
91% (87-85; 95% CI) and accuracy 88% (84-92; 95% CI) was observed (Table 1).  In 
addition, considering the accuracy of the two approaches in detecting not only tumour 
patients but also high-risk adenomas, the RT FL-DNA approach confirms a slightly 
higher sensitivity and specificity (Table 1). 
 
Comparison between iFOBT and RT FL-DNA values in relation to clinical 
pathologic characteristics 
 Our series in this work, in accordance with the conclusions of the 2010 study 
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performed by Calistri et al. (19) consists of individuals with positive and negative and 
iFOBT values.  Between positive iFOBT the median value is 432 ng/ml values, ranging 
from 100 to 3811 ng/ml. Individuals with no lesions and low-risk adenomas patients 
showed the lowest median iFOBT value of 4 ng/ml, both ranged from 0-1000 ng/ml.    
In patients with high-risk adenomas a higher median value was recorded of 13 ng/ml; 
ranging from 0-1000 ng/ml. Considered overall, the median iFOBT value for these three 
subgroups was much lower than that observed for cancer patients 1000 ng/ml, ranging 
from 0 to 3811 ng/ml  (P < 0.0001) (Table 2).  
 Similar results were observed for the RT FL-DNA values. In particular, median 
values were comparable for individuals with no lesions (2 ng/reaction, ranging from      
0-2140 ng/reaction) or with low and high-risk adenomas (1 ng/reaction ranging from    
0-31 ng/reaction and from 0-75 ng/reaction, respectively), and were > 4-fold higher   
(49 ng/reaction ranging from 0-1304 ng/reaction) in cancer patients (P < 0.0001) (Table 
2).  
 A breakdown analysis for clinical and pathological subgroups was performed with 
explorative intent. No differences were noted between healthy donors without any 
benign diseases or lesions and healthy donors with diverticula, haemorrhoids, 
inflammatory bowel disease or benign polyps (data not shown). Moreover, there are no 
significant differences in the FL-DNA value in patients with tumour or adenomas as a 
function of characteristics such as size, stage, dimension, localisation and number of 
lesions. The relationship between iFOBT and RT FL-DNA values within the different 
clinical and pathologic subgroups was investigated separately in adenomas and cancer 
patients, but no significant differences were detected (Tables 3 and 4).  
iFOBT and FL-DNA combination analysis 
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 Finally, we evaluated whether the combination of iFOBT and FL-DNA could 
improve our ability to predict the presence of a tumour and/or high risk adenomas. 
According to the diagnostic relevance of faecal haemoglobin and FL-DNA as 
independent variables, we tested whether or not, and to what extent, the FL-DNA assay 
could improve iFOBT diagnostic accuracy (Table 5 and Supplementary Fig. S1A and 
S1B). In contrast to our previous work, (19) in this study, the analysis was extended 
negative iFOBT values. All iFOBT values were divided into three main subgroups: 0-99 
ng/ml; 100-432 ng/ml and > 432 ng/ml, while FL-DNA results were divided into three 
classes according to different cut-off values (0-9, 10-30, and ≥ 30 ng/reaction), 
suggested in the previous paper (19). In the negative-iFOBT subgroup, the pre-test 
probability of there being a tumour was around 13%, but FL-DNA did not add any 
useful information. Furthermore, in the intermediate positive iFOBT subgroup, with its 
12% overall probability of having cancer, the breakdown analysis as a function of the 
higher RT FL-DNA subgroup brings the probability of having a tumour to 76%. 
Specifically, in the last iFOBT subgroup, with its 38% overall probability of having 
cancer, breakdown analysis as a function of the last RT FL-DNA subgroup highlighted 
the probability of having colorectal cancer as 93% (Table 5). Interestingly, the 
combination between CRC and high risk adenomas increased the post-test probability 
values of having a disease in association with the higher RT FL-DNA values at 76%, 
85% and 94% for all the three main iFOBT subgroups, respectively (Table 5). 
In view of the fact that the best RT FL-DNA cut-off was  slightly lower than that of                 
CE FL-DNA, we performed the iFOBT and FL-DNA combination analysis considering 
different cut-off ranges (0-14; 15-24; ≥25 ng/reaction).  Substantially different results 
were not observed (Supplementary Table S1).  
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Discussion 
 iFOBT is the most widely used method in screening programmes, although it 
presents some limits in terms of accuracy. The most important hallmark of iFOBT is 
bleeding, which may be intermittent and a largely unspecific event and may lead to 
diagnostic errors (21). Conversely, a high number of cells are continuously released into 
the intestinal lumen every day and biomolecular analysis of genomic DNA extracted 
from stool specimens could be an alternative approach to improve the early diagnosis of 
colorectal pre-neoplastic and neoplastic patients (22).  
 In previous studies, we demonstrated that DNA integrity analysis of stools extracted 
by a manual approach could represent an alternative tool to the early detection of 
colorectal lesions (17, 18). In this work, we developed a more user-friendly approach to 
analysing DNA integrity based upon semi-automatic DNA extraction and Real Time 
PCR. Our results show that DNA integrity status evaluated using the RT FL-DNA assay 
and extracted using a semi-automatic approach could be considered as a sensitive and 
specific marker for early CRC detection. Moreover, we observed that RT FL-DNA was 
more accurate than the previous CE FL-DNA method in detecting high risk-adenomas. 
 This new RT FL-DNA method was compared not only with positive iFOBT values, 
but also with negative values of the diagnostic iFOBT so as to evaluate if a multiple 
approach could increase predictive accuracy in detecting tumours and high-risk 
adenomas, thus overcoming the limitations of the occult blood test detection. In the 
positive-iFOBT values subgroups, faecal RT FL-DNA provided more accurate 
diagnostic information and identified subgroups with different probability of having a 
tumour. Interesting results were also obtained by evaluating high-risk adenoma and 
tumour subgroups together. iFOBT values in combination with subsequent higher 
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values of RT FL-DNA in the Fagan nomogram improved the risk of disease in terms of 
post-test probability.  
 Our results would seem to indicate that this molecular method could be a useful 
addition to the conventional iFOBT in CRC screening programmes.  However, the 
transfer of new diagnostic approaches to clinical practice is often hindered by problems 
relating to  time-consuming methodologies and costs of  individual tests.   Song et al. 
(23) estimated the costs of faecal molecular tests as being between $350 and $795, 
whereas the cost of colonoscopies ranges from $1,200 to $1,800, depending upon the 
localisation of the lesions.  
 Studies assessing the best cost-benefit ratio through the creation of a computer 
simulation of screening for CRC and polyps indicate that no useful results are yet 
available for molecular DNA tests considering the current price. Using simulation 
models, it has been calculated, for example, that a molecular test submitted every two 
years and with a sensitivity of 65% for CRC and 40% for advanced adenoma, with a 
specificity of 95%, could be an alternative to colonoscopy only if it costs less than $200 
(24). In all likelihood, the cost of the RT FL-DNA test is significantly less than the 
hypothetical costs suggested by Song et al. Moreover, this cost could probably be 
further reduced in the case of its large-scale use, as was the case for the hepatitis B virus 
in 1990 (23).   
 In conclusion, the limitations of this approach include the unknown frequency at 
which the tests should be carried out and the number of stool samples that need to be 
analysed at specific time points for each individual. It should be noted that the adenoma 
risk classification was based only upon pathologic parameters, which needed to be 
improved.  Its evaluation through clinical multicenter trials in order to verify its real 
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effectiveness with standard approaches such as iFOBT, colonoscopy and 
sigmoidoscopy, before it can be implemented into clinical practice, may be an important 
starting point. It could also be used to enhance the personalised surveillance intervals in 
individuals undergoing the current standard CRC screening methods. Innovative and 
personalised diagnoses and therapies against cancer are the main aims of all future 
clinical trials. 
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Table 1.  A comparison between CE FL-DNA and RT FL-DNA to evaluate the best valid method to quantify FL-DNA from stool samples in 
detecting tumour and tumour and high risk adenomas patients. 
 
Abbreviation: CE-FL DNA: capillary electrophoresis fluorescence long DNA; RT FL-DNA: real time PCR fluorescence long DNA; 95% CI: 95% confidence intervals; 
CRC: colorectal cancer patients; HRA: high risk adenomas patients; Other1: high and low risk adenomas and healthy subjects; Other2: low risk adenomas and healthy 
subjects. Sensitivity: true positive rates; Specificity: true negative rates; Accuracy: number of true positive plus number of true negative, divided by the total series. 
CE FL-DNA RT-FL-DNA 
Cut-offs 
(ng) 
CRC Others1 %  Sensitivity 
(95% CI) 
% 
Specificity 
(95% CI) 
% Accuracy 
(95% CI) 
CRC Others1 % Sensitivity
(95% CI) 
% Specificity
(95% CI) 
% Accuracy 
(95% CI) 
Positive Positive 
≥10 21 123 91(73-97) 44 (37-50) 48 (42-54) 17 44 74 (53-87) 80 (74-85) 79 (74-84) 
≥15 18 71 78 (58-90) 67 (61-73) 68 (62-74) 16 29 70 (49-84) 87 (82-91) 85 (80-89) 
≥20 16 46 70 (49-84) 79 (73-84) 78 (72-83) 14 19 61 (41-78) 91 (87-85) 88 (84-92) 
≥25 13 34 57 (37-74) 84 (79-89) 82 (76-86) 13 12 57 (37-74) 94 (91-97) 91 (87-94) 
≥30 12 21 52 (33-71) 90 (86-94) 87 (82-90) 13 5 57 (37-74) 98 (95-99) 94 (90-96) 
 
CRC + HRA Others2 
   
CRC + HRA Others2
   
Positive Positive 
≥10 40 104 71 (58-82) 44 (37-51) 50 (44-55) 23 38 41 (29-54) 79 (73-85) 71 (65-76) 
≥15 27 62 48 (36-61) 66 (59-73) 62 (56-68) 22 23 39 (28-52) 88 (82-92) 76 (71-81) 
≥20 23 39 41 (29-54) 79 (72-84) 70 (64-76) 17 16 30 (20-43) 91 (86-95) 77 (72-82) 
≥25 18 29 32 (21-45) 84 (78-89) 72 (66-77) 15 10 27 (17-40) 95 (90-97) 79 (74-84) 
≥30 15 18 27 (17-40) 90 (85-94) 76 (70-81) 15 3 27 (17-40) 98 (95-99) 82 (76-86) 
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Table 2. RT FL-DNA and iFOBT values in 241 individuals with malignant, pre-malignant or no lesions 
  N  RT FL-DNA iFOBT 
  
241 
Median value  
(ng/reaction) (range) 
Median value  
(ng/ml) (range) 
No lesions 149 2 (0-2140) 4 (0-1000) 
Low-risk adenomas 35 1 (0-31) 4 (0-1000) 
High-risk adenomas 34 1 (0-75) 13 (0-1000) 
Colorectal cancer 23 49 (0-1304) 1000 (0-3811) 
  P < 0.0001 P < 0.0001 
Abbreviation: RT FL-DNA, real time PCR fluorescence long DNA; iFOBT, immunochemical faecal occult blood test. 
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               Table 3.  RT FL-DNA and iFOBT values in adenoma patients according to clinical-pathological characteristics 
 
Cases 
RT FL-DNA 
(ng/reaction) 
 iFOBT 
(ng/ml) 
 
 
(N=69) Median (range) P Median (range) P 
Gender      
Male 43 0.68 (0-30.6)  9 (0-1000)  
Female 26 1.37 (0-74.5) 0.871 8 (0-1000) 0.663 
Patient classification      
Low-Risk 35 1.45 (0-30.6)  4 (0-1000)  
High-Risk 34 0.65 (0-74.5) 0.379 13 (0-1000) 0.138 
Lesion dimension      
0-0.9 cm 40 1.47 (0-30.6)  4.5 (0-1000)  
≥ 1 cm 27 0.62 (0-74.5) 0.566 16 (0-753) 0.144 
Number of lesions      
Single 48 0.88 (0-74.5)  7 (0-1000)  
Multiple 20 1.37 (0-30.6) 0.446 10.5 (0-753) 0.361 
Lesion localisation      
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Descending+transverse 11 0.50 (0-26.8)  2 (0-75)  
Ascending 22 0.29 (0-30.6)  15 (0-1000)  
Mixed 5 1.05 (0-19.9) 0.637 1 (0-485) 0.169 
              Abbreviation: RT FL-DNA, real time PCR fluorescence long DNA; iFOBT, immunochemical faecal occult blood test.  
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Table 4.  RT FL-DNA and iFOBT values in CRC patients according to clinical-pathological characteristics 
 
Cases 
RT FL-DNA 
(ng/reaction) 
 
iFOBT 
(ng/ml) 
 
 (N=23) Median (range) P Median (range) P 
Gender   
 
 
 
Male 17 40.23 (0.0-1303.95)  1000 (1-3707)  
Female 6 60.39 (0.0-387.14) 0.528 1000 (0-3811) 0.807 
Duke’s stage      
A 7 40.23 (1.88-323.04)  1000 (219-2786)  
B 11 64.46 (1.56-1303.95)  1000 (1-3811)  
C+D 2 33.49 (8.60-58.38) 0.345 1000 (1000-1000) 0.960 
TNM classification      
T1 7 40.23 (1.88-323.04)  1000 (219-2786)  
T2 5 113.94 (51.5-387.14)  534 (1-1000)  
T3 8 38.17 (1.56-1303.95) 0.170 1464 (396-3811) 0.052 
Lesion dimension      
0-0.9 cm 5 64.46 (40.23-202.57)  2018 (217-3707)  
≥1 cm 13 58.38 (1.88-1303.95) 0.628 1000 (241-3811) 0.922 
Abbreviation: RT FL-DNA, real time PCR fluorescence long DNA; iFOBT, immunochemical faecal occult blood test; N.A., not applicable; 
TNM, tumour-node-metastasis.  
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Table 5. Colorectal cancer and colorectal cancer plus high risk adenoma  prevalence as a function of FL-DNA evaluation and negative iFOBT and positive 
iFOBT separated by the median value of all positive iFOBT detected. 
 
 Colorectal cancer 
RT FL-DNA 
Yes 
N (%) 
No 
N (%) 
Likelihood ratio 
(95% CI) 
iFOBT <100 
Post-test probability 
(pre-test=0.0128) 
iFOBT 100-432 
Post-test probability 
(pre-test=0.116) 
iFOBT >432 
Post-test probability 
(pre-test=0.381) 
0-9 6 (26.1) 174 (79.8) 0.327 (0.156-0.683) 0.004 0.041 0.168 
10-30 4 (17.4) 39 (17.9) 0.972 (0.398-2.374) 0.012 0.113 0.374 
≥30 13 (56.5) 5 (2.3) 24.643 (17.210-35.288) 0.242 0.764 0.938 
Total 23 (100) 218 (100)     
 
 Colorectal cancer and high-risk adenoma 
RT FL-DNA 
Yes 
N (%) 
No 
N (%) 
Likelihood ratio 
(95% CI) 
iFOBT <100 
Post-test probability
(pre-test=0.160) 
iFOBT 100-432 
Post-test probability 
(pre-test=0.256) 
iFOBT >432 
Post-test probability 
(pre-test=0.500) 
0-9 34 (59.7) 146 (79.4) 0.752 (0.527-1.072) 0.125 0.206 0.429 
10-30 8 (14.0) 35 (19.0) 0.738 (0.387-1.408) 0.123 0.203 0.425 
≥30 15 (26.3) 3 (1.6) 16.140 (10.449-24.931) 0.755 0.847 0.942 
Total 57 (100) 184 (100)     
Abbreviation: RT FL-DNA, real time PCR fluorescence long DNA; iFOBT, immunochemical faecal occult blood test; 95% CI, 95% confidence intervals. 
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Figure legends 
 
 
 
 
Figure 1.  ROC curve.  ROC curve of FL-DNA and RT-DNA analyses for the complete series of stool 
samples. 
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